Glycogen Phosphorylase Inhibitor N-(3,5-Dimethyl-Benzoyl)-N’-(β-D-Glucopyranosyl)Urea Improves Glucose Tolerance under Normoglycemic and Diabetic Conditions and Rearranges Hepatic Metabolism
Chow-fed (n = 7/7, 6 months of age) and HFD-fed (n = 9/9, 6 months of age) C57/Bl6J male mice underwent vehicle or KB228 treatment. 2 hours post-treatment livers and gastrocnemius muscles were removed and homogenized. (A, B) In liver homogenates from chow-fed (A) or HFD-fed (B) mice UCP2 mRNA and protein levels were assayed in RT-qPCR reactions and Western blotting. (C, D) In skeletal muscle homogenates from chow-fed (C) or HFD-fed (D) mice UCP2 mRNA levels were measured in RT-qPCR reactions. (E) Differentiated C2C12 myoblasts were treated with 3 µM of KB228 for 8 hours then UCP2 expression was determined in RT-qPCR reactions. Error is given as SD on panel E. * and *** indicate statistically significant difference between vehicle and GPi-treated groups at p<0.05, or p<0.001, respectively.